Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers

PHASE3TerminatedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

July 8, 2020

Study Completion Date

July 21, 2020

Conditions
COVIDSARS PneumoniaCytokine Release Syndrome
Interventions
DRUG

Tocilizumab

Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.

Trial Locations (7)

04004030

HCOR -Hospital do Coracao, São Paulo

Unknown

UNIFESP, São Paulo

HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, São Paulo

HIAE - Hospital Israelita Albert Einstein, São Paulo

HSL - Hospital Sírio Libanês, São Paulo

01323001

HAOC - Hospital Alemao Oswaldo Cruz, São Paulo

01323900

Beneficência Portuguesa de Sao Paulo, São Paulo

Sponsors
All Listed Sponsors
collaborator

Hospital do Coracao

OTHER

collaborator

Hospital Israelita Albert Einstein

OTHER

collaborator

Hospital Sirio-Libanes

OTHER

collaborator

Hospital Alemão Oswaldo Cruz

OTHER

collaborator

Brazilian Research In Intensive Care Network

NETWORK

collaborator

Hospital Moinhos de Vento

OTHER

collaborator

Brazilian Clinical Research Institute

OTHER

collaborator

Federal University of São Paulo

OTHER

lead

Beneficência Portuguesa de São Paulo

OTHER